Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 3 for:    norcys | Bladder Cancer
Previous Study | Return to List | Next Study

Nordic Cystectomy Study I - Neutrophil-lymphocyte Ratio (NLR) (NorCys-NLR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04523025
Recruitment Status : Recruiting
First Posted : August 21, 2020
Last Update Posted : November 25, 2020
Nordic Urothelial Cancer Group
Information provided by (Responsible Party):
Turku University Hospital

Brief Summary:

Around 7200 cases of Muscle Invasive Bladder Cancer are diagnosed annually in the Nordic countries combined. Muscle Invasive Bladder Cancer is an aggressive disease and it is linked with high mortality rates. The golden standard of treatment is radical cystectomy (RC) (the surgical removal of the bladder) and radical removal of lymph nodes in the pelvis. In addition to surgical treatment, and especially in cases where the tumour invades tissues surrounding the bladder or lymph nodes, chemotherapy is recommended. Chemotherapy can be administered before or after surgery, in a neoadjuvant (NAC) or adjuvant setting (AC). Although most patients recover well from surgery, there are significant risks regarding radical cystectomy. The greatest challenges in planning the treatment are making individual risk assessments and prognosis for the treated patients. Neoadjuvant chemotherapy is also insufficiently used and it is hard to predict how the tumour responds to chemotherapy.

The purpose of this study is to collect prospective clinical data on radical cystectomy -patients in co-operation with other Nordic countries: Sweden, Denmark, Iceland and Norway. The collected data is used to validate existing prediction tools and discover novel tools for prediction of morbidity related to RC and prediction of oncological outcome after RC. The study is divided into three sub-studies. The second sub-study is on the preoperative neutrophil-lymphocyte ratio (NLR). Some studies suggest that NLR might be a predictor of oncological outcome of BC after RC. In addition, NLR has been suggested to correlate with NAC response and outcome after NAC and RC. The used cut-off value for NLR has varied between 2.26-3.0.

Patients will be allocated into two groups: low NLR ratio (NLR<3), and high NLR ratio (NLR≥3). The lab test will be retrieved before RC at the time of routine clinical laboratory testing for all patients and also before the initiation of NAC for patients planned to have chemotherapy. The primary end-point is bladder-cancer specific survival and, and secondary endpoints include progression-free, and overall survival.

Condition or disease Intervention/treatment
Bladder Cancer Invasive Bladder Cancer Diagnostic Test: NLR-ratio

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 230 participants
Observational Model: Case-Control
Time Perspective: Prospective
Target Follow-Up Duration: 24 Months
Official Title: Nordic Cystectomy Study I - Prospective Validation of Neutrophil/Lymphocyte Ratio as Predictor of Bladder Cancer Survival Risk After Radical Cystectomy for Bladder Cancer
Actual Study Start Date : August 30, 2020
Estimated Primary Completion Date : August 30, 2025
Estimated Study Completion Date : August 30, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bladder Cancer

Group/Cohort Intervention/treatment
Low NLR-ratio
Patients with low NLR ratio (NLR<3)
Diagnostic Test: NLR-ratio
The ratio of neutrophils and lymphocytes in patients blood sample prior to surgical operation

High NLR-ratio
Patients with high NLR ratio (NLR≥3)
Diagnostic Test: NLR-ratio
The ratio of neutrophils and lymphocytes in patients blood sample prior to surgical operation

Primary Outcome Measures :
  1. Bladder-cancer specific survival [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. Progression-free survival [ Time Frame: 24 months ]
  2. overall survival [ Time Frame: 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult patients with muscle-invasive bladder cancer undergoing radical cystectomy -surgery

Inclusion Criteria:

  1. Histologically confirmed urinary BC planned to be treated with RC with or without neoadjuvant chemotherapy.
  2. Histologically confirmed urinary BC planned to be treated with palliative cystectomy 2) Signed informed consent 3) Patient age >18 years

Exclusion Criteria:

  1. RC for other reasons than BC
  2. Other forms of surgical treatment of BC than RC (e.g. bladder resection).
  3. Patient unwillingness to participate in the study for any reason (i.e. lack of signed consent).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04523025

Layout table for location contacts
Contact: Otto Ettala, MD, PhD 23130280 ext +358
Contact: Ilkka Nikulainen, MD 23137928 ext +358

Layout table for location information
University Hospital of Turku, Hospital Distric of Southwest Finland Recruiting
Turku, Southwest Finland, Finland, 20521
Contact: Otto Ettala, MD, PhD    23130280 ext +358   
Sponsors and Collaborators
Turku University Hospital
Nordic Urothelial Cancer Group
Layout table for investigator information
Principal Investigator: Peter Boström, MD, PhD Turku University Hospital
Layout table for additonal information
Responsible Party: Turku University Hospital Identifier: NCT04523025    
Other Study ID Numbers: T197/2020
First Posted: August 21, 2020    Key Record Dates
Last Update Posted: November 25, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Urinary Bladder Diseases
Urologic Diseases